Analyzing Xcorporeal (OTCMKTS:XCRP) & Beta Bionics (NASDAQ:BBNX)

Xcorporeal (OTCMKTS:XCRP) and Beta Bionics (NASDAQ:BBNX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk.

Profitability

This table compares Xcorporeal and Beta Bionics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xcorporeal	N/A	N/A	N/A
Beta Bionics	-87.89%	-35.72%	-20.69%

Earnings and Valuation

This table compares Xcorporeal and Beta Bionics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xcorporeal	N/A	N/A	N/A	N/A	N/A
Beta Bionics	$65.12 million	19.74	-$54.76 million	($4.37)	-6.68

Xcorporeal has higher earnings, but lower revenue than Beta Bionics.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Xcorporeal and Beta Bionics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xcorporeal	0	0	0	0	0.00
Beta Bionics	1	3	8	1	2.69

Beta Bionics has a consensus price target of $28.78, indicating a potential downside of 1.41%. Given Xcorporeal’s higher possible upside, equities research analysts clearly believe Xcorporeal is more favorable than Beta Bionics.

About Xcorporeal

Xcorporeal, Inc. is in the process of liquidation and dissolution, pursuant to the plan adopted by board of directors of the company on February 4, 2010. The company has formed the liquidating trust, Xcorporeal, Inc. Liquidating Trust, and transferred all of its assets to the trust for the purpose of completing the liquidation and dissolution of the company. Previously, it operated as a medical device company, which was engaged in the development of an extra-corporeal platform technology to be used in devices to replace the function of various human organs. Xcorporeal, Inc. was founded in 2001 and is based in Lake Forest, California.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.